X4 Pharmaceuticals (XFOR) Stock
Early stage biotech developing treatments for cancer and inflammation. Here's the price, business snapshot, and what's worth knowing about X4 Pharmaceuticals in October 2026.
X4 Pharmaceuticals Inc (XFOR) is a small-cap biotechnology company developing therapies that modulate the CXCR4 pathway, a target implicated in cancer and inflammatory disease. With a market capitalisation of roughly $36 million, X4 is an early-stage, clinical-stage company whose near-term value is largely driven by trial readouts, regulatory milestones and potential partnerships or licensing deals. Investors should note the typical biotech risk profile: binary clinical outcomes, high cash burn, potential dilution from future financing and low liquidity in the shares. Upside can come from positive efficacy or safety data and commercial deals, but there is a meaningful chance of setbacks. This summary is educational, not investment advice. Prospective investors should consider suitability for their risk tolerance, review company filings and consult a qualified financial adviser before making decisions.
X4 Pharmaceuticals (XFOR) Stock Forecast
Analyst price target, next 12 months
$6.00
+112.0% vs today's $2.83
Price range over the last 12 months
Close to its 12-month low
Analysts covering X4 Pharmaceuticals have a consensus 12-month target of $6.00, above the current price of $2.83.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 9 Sep 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying X4 Pharmaceuticals’ stock with a target price of $6, indicating significant growth potential.
Financial Health
X4 Pharmaceuticals is doing well, showing strong revenue and cash flow, with high profit margins.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Targeted CXCR4 approach
X4’s programmes centre on CXCR4 modulation, a mechanism with potential in oncology and inflammation — though clinical proof is required and outcomes can vary.
Clinical readouts matter
Near-term catalysts are trial results and regulatory steps; positive data can boost interest, but negative readouts can have the opposite effect.
Small-cap considerations
With a market cap around $36m, the stock can be volatile and illiquid; investors should weigh financing and dilution risk alongside opportunity.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
